Equities research analysts predict that Repligen Co. (NASDAQ:RGEN) will report sales of $63.01 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Repligen’s earnings, with the lowest sales estimate coming in at $56.00 million and the highest estimate coming in at $70.06 million. Repligen reported sales of $47.73 million in the same quarter last year, which would suggest a positive year over year growth rate of 32%. The company is expected to issue its next quarterly earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Repligen will report full year sales of $254.96 million for the current year, with estimates ranging from $245.10 million to $265.60 million. For the next financial year, analysts forecast that the firm will report sales of $299.10 million, with estimates ranging from $285.00 million to $314.05 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Repligen.
Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.26 by $0.02. Repligen had a return on equity of 6.35% and a net margin of 10.11%. The company had revenue of $60.63 million for the quarter, compared to analyst estimates of $55.09 million. During the same period last year, the company posted $0.17 earnings per share. The firm’s revenue was up 35.3% compared to the same quarter last year.
NASDAQ:RGEN traded down $0.99 during mid-day trading on Monday, hitting $86.80. The company had a trading volume of 310,761 shares, compared to its average volume of 603,326. The business has a fifty day simple moving average of $80.78. The company has a quick ratio of 1.84, a current ratio of 2.18 and a debt-to-equity ratio of 0.03. Repligen has a 1 year low of $45.00 and a 1 year high of $89.22. The company has a market capitalization of $4.15 billion, a price-to-earnings ratio of 118.90, a price-to-earnings-growth ratio of 5.30 and a beta of 1.10.
In related news, Director Glenn L. Md Cooper sold 5,000 shares of Repligen stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $66.94, for a total value of $334,700.00. Following the completion of the transaction, the director now directly owns 35,975 shares in the company, valued at $2,408,166.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karen A. Dawes sold 1,295 shares of Repligen stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $77.35, for a total value of $100,168.25. Following the completion of the transaction, the director now owns 118,329 shares of the company’s stock, valued at $9,152,748.15. The disclosure for this sale can be found here. 1.70% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the stock. Huntington National Bank acquired a new position in Repligen in the first quarter worth about $25,000. Royce & Associates LP grew its stake in Repligen by 40.6% in the first quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 145 shares in the last quarter. Mascoma Wealth Management LLC acquired a new position in Repligen in the first quarter worth about $41,000. Private Capital Group LLC grew its stake in Repligen by 675.3% in the first quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 628 shares in the last quarter. Finally, South Dakota Investment Council acquired a new position in Repligen in the first quarter worth about $83,000. Institutional investors and hedge funds own 85.53% of the company’s stock.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
See Also: Book Value Per Share – BVPS
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.